Shares of Raleigh's BioDelivery plummet 30 percent

Raleigh drug developer BioDelivery Sciences International (Nasdaq: BDSI) lost more than a quarter of its market value Monday after it announced disappointing trial results on an experimental pain treatment under development. Shares traded down more than 30 percent from Friday’s close at one point and hovered around the $10 mark Monday morning. Shares closed at nearly $14 on Friday and have been as high as $18.48 in the past year. BioDelivery had tested its Clonidine Topical Gel as a treatment…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news